Video

When to Initiate Treatment for ITP

For High-Definition, Click

The goal of idiopathic thrombocytopenic purpura (ITP) treatment, explains Ivy Altomare, MD, is to treat active bleeding or reduce the risk of bleeding. Determining when to treat a patient with ITP depends on several factors, says Howard A. Liebman, MD, including patient preference and clinical manifestations.

The majority opinion is that patients should consider treatment, if they are not bleeding, only when platelet counts are less than 30,000. Keith McCrae, MD, states that a sedentary person’s platelet count can go quite low, perhaps even below 20,000, before therapy is required. Individuals with a platelet count around 30,000 do not usually have clinically significant bleeding that would put them at risk.

It is also important to consider patient characteristics, such as age and comorbidities, Altomare notes. Older individuals with coronary artery disease taking antiplatelet therapy may be at higher risk of bleeding.

Related Videos
Ashkan Emadi, MD, PhD
Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, discuss factors that influence later-line treatment choices in chronic myeloid leukemia.
Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, on the implications of the FDA approval of asciminib in newly diagnosed CP-CML.
Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma
Eunice S. Wang, MD
Nosha Farhadfar, MD, and Chandler Park, MD, FACP
Eunice Wang, MD, and Chandler Park, MD, FACP
Muhamed Baljevic, MD, FACP and Jorge Cortes, MD, discuss upcoming studies and emerging data being presented at the 2024 ASH Annual Meeting.
Minoo Battiwalla, MD, MS
Farrukh Awan, MD, discusses treatment considerations with the use of pirtobrutinib in previously treated patients with hematologic malignancies.